Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

News

Ineos Oxford Institute makes award to OVG project tackling antimicrobial resistance

The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over £2m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.

Typhoid vaccine trial confirms sustained protection for older children

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.

New campaign launched to encourage vaccine uptake

Parents are being urged to get their children vaccinated as experts launch a campaign to boost uptake in the UK amid rising cases of whooping cough and measles. Researchers at the Oxford Vaccine Group, which is part of the University of Oxford, have developed an animation that, they say, focuses on the "critical role" whooping cough jabs play in protecting against infection, which can cause serious complications such as pneumonia.

Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation

Ground-breaking research revealed in new video

The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.

Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus

Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.

Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences

Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.

More babies could die if rates of vaccination against whooping cough don’t increase

Babies and the most vulnerable are at risk of death if vaccination rates for whooping cough don't increase, according to experts at the University of Oxford.

Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.

How the Information Security Office and the National Cyber Security Centre keeps Oxford's research secure post-pandemic

Oxford University's Information Security Office (InfoSec) invited the NCSC to Oxford to thank them for the work they did that kept Oxford’s vaccine research secure.

Ground-breaking study reveals how COVID-19 vaccines prevent severe disease

A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.

Oxford hosts Belgian vaccine experts

Researchers from Oxford Vaccine Group and the Pandemic Sciences Institute welcomed a delegation of vaccine researchers from Belgium to further UK-Belgian collaboration on vaccine development and manufacture.

Advancing a malaria vaccine for better global health outcomes

Professor Sue Ann Costa Clemens CBE, Chair of Global Health at the Department of Paediatrics and Head of Oxford Latam Research Group – a collaboration between Oxford and Brazil, aimed at strengthening our commitment to global health – met with His Excellency Antonio Patriota, Brazilian Ambassador to the UK, to discuss the co-development of a Malaria vaccine and advance public health outcomes in Brazil.

New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites

Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.

Student wins award for Individual Excellence in Clinical Data Management

Many congratulations to Yama Farooq Mujadidi, DPhil student and Clinical Trials IT & Development Lead at the Oxford Vaccine Group, who has been awarded the prize for Individual Excellence by the Association for Clinical Data Management.

Oxford University Professors to lecture on new course in 'Translational Science' at three Brazilian institutions

The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.

FCDO Minister meets with vaccine researchers

Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.

First in-human vaccine trial for Nipah virus

The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.

OVG professor named in New Year's Honours list

Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.

Oxford Vaccine Group receives £7.8 million in research funding to fight pandemic and epidemic threats

Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.

Load More